Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NewGenIvf Group LtdNIVF · Entity 38 | Director · Chairman & CEO | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NewGenIvf Group Ltd
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table I · non-derivative | Direct | 146,132 |
Reported balance
After 2026-10-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-05 · Exercise / conversion · Acquired 139,811 · Balance 146,132 F1: The Class B Ordinary Shares were acquired through the exercise of vested stock options ("Options"). The Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and the employee share option agreement, dated July 8, 2026 and August 17, 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options were exercised by the Reporting Person on October 5, 2026. F2: The share amounts reported herein have been adjusted to reflect two 1-for-3 reverse-stock-splits implemented by the Issuer on July 6, 2026 and September 1, 2026. The amount of securities beneficially owned following the reported transaction reflects: (i) 139,811 Class B Ordinary Shares issued under this exercise, and (ii) 6,321 Class B Ordinary Shares historically held (adjusted from the 56,881 pre-reverse-split shares previously reported). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2033-07-08 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Exercise / conversion · Disposed 49,098 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2033-08-17 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 90,713 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares were acquired through the exercise of vested stock options ("Options"). The Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and the employee share option agreement, dated July 8, 2026 and August 17, 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options were exercised by the Reporting Person on October 5, 2026.
F2: The share amounts reported herein have been adjusted to reflect two 1-for-3 reverse-stock-splits implemented by the Issuer on July 6, 2026 and September 1, 2026. The amount of securities beneficially owned following the reported transaction reflects: (i) 139,811 Class B Ordinary Shares issued under this exercise, and (ii) 6,321 Class B Ordinary Shares historically held (adjusted from the 56,881 pre-reverse-split shares previously reported).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 14:58 UTC | NewGenIvf Group Ltd NIVF · Entity 38 | Exercise / conversionStock Options (Right to Buy) · Derivative | 90,713 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-107053 · ownership.xml · derivative · entry 3 Siu Wing Fung Alfred · CIK 0002009969 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Ordinary Shares · 90,713 shares Expires 2033-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 14:58 UTC | NewGenIvf Group Ltd NIVF · Entity 38 | Exercise / conversionStock Options (Right to Buy) · Derivative | 49,098 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-107053 · ownership.xml · derivative · entry 2 Siu Wing Fung Alfred · CIK 0002009969 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Ordinary Shares · 49,098 shares Expires 2033-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 14:58 UTC | NewGenIvf Group Ltd NIVF · Entity 38 | Exercise / conversionClass B Ordinary Shares | 139,811 | $0.00 | $13.98 |
DisclosureSEC source: 0001213900-26-107053 · ownership.xml · nonDerivative · entry 1 Siu Wing Fung Alfred · CIK 0002009969 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: The Class B Ordinary Shares were acquired through the exercise of vested stock options ("Options"). The Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and the employee share option agreement, dated July 8, 2026 and August 17, 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options were exercised by the Reporting Person on October 5, 2026. F2 · balance_after: The share amounts reported herein have been adjusted to reflect two 1-for-3 reverse-stock-splits implemented by the Issuer on July 6, 2026 and September 1, 2026. The amount of securities beneficially owned following the reported transaction reflects: (i) 139,811 Class B Ordinary Shares issued under this exercise, and (ii) 6,321 Class B Ordinary Shares historically held (adjusted from the 56,881 pre-reverse-split shares previously reported). Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:01 UTC | NewGenIvf Group Ltd NIVF · Entity 38 | GrantStock Options (Right to Buy) · Derivative | 272,140 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-091209 · ownership.xml · derivative · entry 1 Siu Wing Fung Alfred · CIK 0002009969 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,787 Underlying: Class B Ordinary Shares · 272,140 shares Expires 2033-08-17 F1 · derivative.exercise_date: Reflects the grant of stock options to acquire 272,140 Class B Ordinary Shares of the Issuer at an exercise price of US$0.0001 per share, made pursuant to the Issuer's 2024 Share Incentive Plan and the Employee Stock Option Agreement, dated August 17, 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options vest upon grant and expire on August 17, 2033 (Grant Date + 7 years), subject to earlier termination as provided in the Option Agreement and the Plan. Read SEC document |
| July 08, 2026 Filed Jul 9, 2026 19:30 UTC | NewGenIvf Group Ltd NIVF · Entity 38 | GrantEmployee Share Options · Derivative | 73,647 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-076685 · ownership.xml · derivative · entry 1 Siu Wing Fung Alfred · CIK 0002009969 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,647 Underlying: Class B ordinary shares · 73,647 shares Expires 2033-07-08 F1 · shares: The Employee Share Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and an employee share option agreement, dated July 8, 2026, between the Issuer and the Reporting Person (the "Option Agreement"). F1 · price: The Employee Share Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and an employee share option agreement, dated July 8, 2026, between the Issuer and the Reporting Person (the "Option Agreement"). F2 · derivative.exercise_date: The Employee Share Options vest monthly, over 36 months, with the first tranche of 10% vesting on August 8, 2026. Thereafter, the Employee Share Options vest monthly in tranches of approximately 2.6%. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 15:14 UTC | NewGenIvf Group Ltd NIVF · Entity 38 | Exercise / conversionClass B Ordinary Shares | 56,851 | $0.00 | $5.69 |
DisclosureSEC source: 0001213900-26-065596 · ownership.xml · nonDerivative · entry 1 Siu Wing Fung Alfred · CIK 0002009969 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: The Class B Ordinary Shares were acquired through the exercise of vested stock options ("Options"). The Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and the employee share option agreement, dated 4 May 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options were accelerated by resolution of the independent directors of the Board of Directors on 26 May 2026, and were exercised by the Reporting Person on 4 June 2026. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:01 UTC | NewGenIvf Group Ltd NIVF · Entity 38 | GrantStock Options (Right to Buy) · Derivative | 56,851 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-052792 · ownership.xml · derivative · entry 1 Siu Wing Fung Alfred · CIK 0002009969 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,881 Underlying: Class B Ordinary Shares · 56,851 shares Expires 2033-05-04 F1 · derivative.exercise_date: Reflects the grant of stock options to acquire 56,851 Class B Ordinary Shares of the Issuer at an exercise price of US$0.0001 per share, made pursuant to the Issuer's 2024 Share Incentive Plan and the Employee Stock Option Agreement, dated 4 May 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options vest as follows: 5,685 options on 4 June 2026 (First Tranche); 1,462 options on the 4th day of each month from 4 July 2026 through 4 April 2029 (34 monthly tranches); and 1,458 options on 4 May 2029 (Final Tranche). The options expire on 4 May 2033, subject to earlier termination as provided in the Option Agreement and the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.